Isofol Medical

0,72 SEK

-0,96 %

Mindre end 1K følgere

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-0,96 %

+1,27 %

+22,97 %

-1,23 %

+4,12 %

-31,72 %

+34,54 %

-91,72 %

-94,66 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Markedsværdi

230,75 mio. SEK

Aktieomsætning

181,67 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

25.8

2026

Delårsrapport Q2'26

12.11

2026

Delårsrapport Q3'26

12.2

2027

Årsrapport '26

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse19.5.2026, 14.45

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

Pressemeddelelse19.5.2026, 11.14

Redeye: Isofol Medical (Q1 Review): Tailwind despite slower recruitment

Eksterne analyser19.5.2026, 07.38

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse19.5.2026, 06.00

Isofol Medical AB (publ) publishes interim report, January – March 2026

Selskabsmeddelelse30.4.2026, 06.00

New number of shares and votes in Isofol

Selskabsmeddelelse15.4.2026, 14.00

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Pressemeddelelse15.4.2026, 07.10

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Selskabsmeddelelse10.4.2026, 06.00

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Selskabsmeddelelse31.3.2026, 15.00

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Selskabsmeddelelse18.3.2026, 12.50

Isofol secures license rights for arfolitixorin in autism

Selskabsmeddelelse13.3.2026, 17.40

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Selskabsmeddelelse11.3.2026, 14.30

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Selskabsmeddelelse9.3.2026, 10.00

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Pressemeddelelse3.3.2026, 07.30

Isofol presents at investor meetings in March

Eksterne analyser25.2.2026, 06.22

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Selskabsmeddelelse24.2.2026, 08.32

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Pressemeddelelse19.2.2026, 08.36

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Selskabsmeddelelse18.2.2026, 06.30

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Eksterne analyser15.1.2026, 12.46

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Pressemeddelelse9.1.2026, 06.30

Isofol participates in the ASCO GI congress

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.